Cargando…

The Kinetics of FMS-Related Tyrosine Kinase 3 Ligand (Flt-3L) during Chemoradiotherapy Suggests a Potential Gain from the Earlier Initiation of Immunotherapy

SIMPLE SUMMARY: Combining chemoradiotherapy with immunotherapy is one of the main milestones in cancer treatment. The optimal sequence to ensure the effectiveness of the treatment is unknown. We investigated the kinetics of FMS-related tyrosine kinase 3 ligand (Flt-3L), a multi-potential haemopoieti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuncman, Łukasz, Orzechowska, Magdalena, Stawiski, Konrad, Masłowski, Michał, Ciążyńska, Magdalena, Gottwald, Leszek, Milecki, Tomasz, Fijuth, Jacek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405787/ https://www.ncbi.nlm.nih.gov/pubmed/36010838 http://dx.doi.org/10.3390/cancers14163844

Ejemplares similares

Dose–volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer
por: Kuncman, Łukasz, et al.
Publicado: (2020)

FMS‐like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer
por: Hasegawa, Hiroko, et al.
Publicado: (2020)

FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritis
por: Ramos, Maria I, et al.
Publicado: (2013)

FMS-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD): a villain among others
por: de Arruda, Vanessa Y.N., et al.
Publicado: (2017)

The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis
por: Steiner, Normann, et al.
Publicado: (2020)

Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets
por: Kasi, Pashtoon M., et al.
Publicado: (2016)

Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification
por: Ke, Yi-Yu, et al.
Publicado: (2015)

Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells
por: Kawase, Tatsuya, et al.
Publicado: (2019)

How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?
por: Perrone, Salvatore, et al.
Publicado: (2023)

Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia
por: Kim, Shin-Young, et al.
Publicado: (2008)

Route of Vaccine Administration Influences the Impact of Fms-Like Tyrosine Kinase 3 Ligand (Flt3L) on Chlamydial-Specific Protective Immune Responses
por: Pais, Roshan, et al.
Publicado: (2019)

Serum Soluble Fms-Like Tyrosine Kinase 1 (sFlt-1) Predicts the Severity of Acute Pancreatitis
por: Dumnicka, Paulina, et al.
Publicado: (2016)

Intertumoral Heterogeneity of Primary Breast Tumors and Synchronous Axillary Lymph Node Metastases Reflected in IHC-Assessed Expression of Routine and Nonstandard Biomarkers
por: Kuncman, Wojciech, et al.
Publicado: (2021)

Pseudogene fms-related tyrosine kinase 1 pseudogene 1 (FLT1P1) cooperates with RNA binding protein dyskeratosis congenita 1 (DKC1) to restrain trophoblast cell proliferation and angiogenesis by targeting fms-related tyrosine kinase 1 (FLT1) in preeclampsia
por: Chi, Zhenjing, et al.
Publicado: (2021)

Fms-like tyrosine kinase 3 is a regulator of the cardiac side population in mice
por: Della Verde, Giacomo, et al.
Publicado: (2021)

High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in FLT3 internal tandem duplication (ITD) negative patients in adult acute myeloid leukaemia: a prospective pilot study from India
por: Sharawat, Surender Kumar, et al.
Publicado: (2016)

FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics
por: Rezaei, Narges, et al.
Publicado: (2017)

ITDetect: a method to detect internal tandem duplication of FMS-like tyrosine kinase (FLT3) from next-generation sequencing data with high sensitivity and clinical application
por: Lee, Sungyoung, et al.
Publicado: (2023)

FMS-like tyrosine kinase 3 is required for dendritic cell development in peripheral lymphoid tissues
por: Waskow, Claudia, et al.
Publicado: (2008)

Detection of nucleophosmin and FMS-like tyrosine kinase-3 gene mutations in acute myeloid leukemia
por: Pazhakh, Vahid, et al.
Publicado: (2011)

Fms-Like Tyrosine Kinase 3 Ligand Controls Formation of Regulatory T Cells in Autoimmune Arthritis
por: Svensson, Mattias N. D., et al.
Publicado: (2013)

FMS-Related Tyrosine Kinase 3 Ligand Promotes Radioresistance in Esophageal Squamous Cell Carcinoma
por: Zhu, Zuoquan, et al.
Publicado: (2021)

Serum Concentrations of Angiopoietin-2 and Soluble fms-Like Tyrosine Kinase 1 (sFlt-1) Are Associated with Coagulopathy among Patients with Acute Pancreatitis
por: Dumnicka, Paulina, et al.
Publicado: (2017)

Rational design and synthesis of 2-(1H-indazol-6-yl)-1H-benzo[d]imidazole derivatives as inhibitors targeting FMS-like tyrosine kinase 3 (FLT3) and its mutants
por: Im, Daseul, et al.
Publicado: (2022)

PB1834: CLEVO: A NON-INTERVENTIONAL STUDY TO INVESTIGATE CLONAL EVOLUTION OF FMS-LIKE TYROSINE KINASE 3 (FLT3) GENE MUTATIONS DURING DISEASE PROGRESSION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Vyas, P., et al.
Publicado: (2022)

Soluble fms-Like Tyrosine Kinase 1 (sFlt1), Endoglin and Placental Growth Factor (PlGF) in Preeclampsia among High Risk Pregnancies
por: Powers, Robert W., et al.
Publicado: (2010)

Fasudil attenuates soluble fms-like tyrosine kinase-1 (sFlt-1)-induced hypertension in pregnant mice through RhoA/ROCK pathway
por: Gu, Ying, et al.
Publicado: (2017)

Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment
por: Hannan, Natalie J., et al.
Publicado: (2017)

Circulating Maternal sFLT1 (Soluble fms-Like Tyrosine Kinase-1) Is Sufficient to Impair Spiral Arterial Remodeling in a Preeclampsia Mouse Model
por: Vogtmann, Rebekka, et al.
Publicado: (2021)

FMS-Like Tyrosine Kinase 3 Ligand Treatment Does Not Ameliorate Experimental Rapidly Progressive Glomerulonephritis
por: Ghali, Joanna R., et al.
Publicado: (2015)

Histone deacetylase inhibitors modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinase-3
por: Zeyn, Yanira, et al.
Publicado: (2023)

Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic
por: Pabianek, Marta, et al.
Publicado: (2022)

Neurotrophin-3 and FLT3 Tyrosine Kinase Receptor in Perinatal Life
por: Malamitsi-Puchner, Ariadne, et al.
Publicado: (2005)

Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy
por: Gurnadi, Jeffry Iman, et al.
Publicado: (2015)

Serum soluble FMS-like tyrosine kinase-1 in ectopic pregnancy
por: Selvarajan, Sathya, et al.
Publicado: (2019)

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
por: Green, Alexa S., et al.
Publicado: (2015)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD(+) AML cell growth
por: Weir, Mark C., et al.
Publicado: (2017)

Molecular Modeling Studies of N-phenylpyrimidine-4-amine Derivatives for Inhibiting FMS-like Tyrosine Kinase-3
por: Ghosh, Suparna, et al.
Publicado: (2021)

Maternal and Perinatal Outcomes Associated With Extremely High Values for the sFlt‐1 (Soluble fms‐Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio
por: Villalaín, Cecilia, et al.
Publicado: (2020)

Novel Ratio Soluble Fms-like Tyrosine Kinase-1/Angiotensin-II (sFlt-1/ANG-II) in Pregnant Women Is Associated with Critical Illness in COVID-19
por: Espino-y-Sosa, Salvador, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nu1uitbnse3bg7k4ab3rapup0l